Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells
Sign Up to like & getrecommendations! Published in 2022 at "Oncology Letters"
DOI: 10.3892/ol.2022.13506
Abstract: The combination of intravenous Proemend® containing fosaprepitant meglumine, a prodrug for fosaprepitant (FAP), and Tween 80 and chemotherapy with anthracyclines, such as epirubicin (EPI), can cause infusion-site adverse events in clinical practice. In immortalized human… read more here.
Keywords: fap epi; infusion site; infusion; site adverse ... See more keywords